Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02684474Unknown

Expanded Access Protocol Using HBOC-201

Role: collaborator

NCT01881503Not ApplicableEnrolling By Invitation

Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

Role: collaborator

NCT03633604Unknown

Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia

Role: collaborator

All 3 trials loaded